cancer chemotherapy


Published on

drugs for cancer

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Cancer is a disease in which there is uncontrolled multiplication and spread within the body of abnormal forms of bodys own cells. It is one of the major causes of death in developed nations atleast 1 in 5 of the population of europe and north america can expect to die of cancer. Cancers are more common in aged people as life expectancy is increasing the incidence of cancers is also increasing, with the present methods of treatment one third of the patients are cured with local modalities of treatment (surgery or irradiation therapy) which are quite effective when the tumor has not metastatized. In metastasis systemic chemotherpy is required along with surgery or irradiation at present 50 % of the patients of cancer can be treated with chemotherapy contributing to cure in 10 -15% of the patients. The terms cancer,malignant neoplasm and malignant tumor are synonymous
  • Treatment of systemic infections /malignancy with specific drugs that have selective toxicity for infecting organisms /malignant cell with no or minimal effects on host cells
  • Hence target selectivity is more difficult in cancer*(exception in lymphoma , there is substantial selectivity)
  • Chemotherapy is essentially required with surgery or irradiation when metastasis has occurred
  • Shrinkage of tumor , alleviation of symptoms
  • Other factors – promoters cocarcinogen, hormones, -- likely hood of mutation
  • Aimed at destroying all the malignant cells, leaving none (lack of participation of host defence/immune response)order kinetics i.e given dose of a drug destroys constant fraction of cells. Term log kill is used to describe this phenomenon e.g leukemia diagnosis made when load of cells is >109 consequently if t/t leads leads to kill 99.99% of the cells then 0.001% i.e 104 cells remain this is equivalent to 5 log kill i.e 100000 fold. At this point patient appears asymptomatic i.e patient is in remission. For most bacterial infections a 5 log fold reduction in no of micro-organisms leads to cure . Since immune system can eradicate remaining bacterial cells. However cancer cells are not so easily destroyed Pharmacological sancturies: leukemia or other tumor cells find sanctury in tissues like CNS in which some chemotherapeutic agents can not enter, because of its transport constraints so pt may require irradiation of cerebrospinal axis or intrathecal administration of drugs at that site Cells of solid tumors can be considered as belonging to 3 compartments Compartment A: Consists of dividing cells, possibly being continously in cell cycle Compartment B: consists of resting cell in Go phase , the cells though not dividing are potentially able to do so Compartment C: cells no longer able to divide but contribute to tumor volume Essentially only cells in compartment A which may form as little as 5 % of some solid tumors are currently susceptible to main available cytotoxic drugs. Log kill: destruction of cancer cells by chemotherapeutic agents follows first
  • Overcrowding of cells: poor blood supply and nutrition and defective access of drugs
  • Heterogenecity of cells –
  • Majority of cytotoxic drugs have more profound effects on rapidly multiplying cells
  • Sulfur mustard in 1917 was first used alkylating agent in WW-1, it was used as chemical warfare and caused severe skin vesication, vesication in mucous membrane , GI ulcerations and myelosupression. The pharmacological actions became evident only after world war 2.
  • All alkylating agents have alkyl groups and they can transfer this alkyl group to suitable receptor site. Alkylating agents in neutral or alkaline solution form highly reactive carbonium ion which is quaternary ammonium derivative(The carbon atom has only six electrons in its outer space so highly reactive). This carbonium ion is highly reactive and can react with groups like NH2, SH, OH or PO4 in physiologically important molecules in cell and render them unavailable for normal metabolic reactions. One more property of this carbonium ion is its nucleophilicity it can react with nucleic acid bases and inhibit DNA synthesis . The nitogen at guanine position 7 is especially more susceptible. So this results in cross linking inhibits DNA replication . Abnormal base pairing (alkylated guanine pairs with thymine instead of cytosine) results in production of defective protein DNA strands breakage – decreased cell proliferation Alkylation also damages RNA and proteins Non cycle specific
  • Alkylation of guanine bases in DNA MOA OF MECHLORETHAMINE
  • Common to the alkylating agents Cytotoxic action in general damage nuclei of growing multiplying cells, hemopoetic system highly susceptible to this action leads to anemia, thrombocytopenia, leukopenia and in toxic doses bonemarrow supression., Net result similar mode of action may differ chlorambucil more effective against lymphoid series and busulfan more effective against myeloid series. These drugs also effect epithelial tissues like cornea, intestinal mucosa leading to desquamation and ulcers Hair follicles- alopecia’sprematogenesis, foetopathy sand ammenorrhoeaImmunosupressant action : supress antibody production Miscellaneous: nausea, vomitingRadiomimetic drugs: actions resemble that of biological or ionizing radiations, all alkylating agents different radiomimetic action.
  • First nitrogen mustard to be used in cancer chemotherapy Very irritant drug: vesicant for skin, eyes, resp tract , should be given only IV , Special care sloughing can occur with extravasation Available as 10 mg HCL with 90 mg NACL should be reconstituted in 10 ml NS or distilled water and given immediately because it becomes active in few minutes Hodkins stage III and stage IV as a part of MOPP mechlor, oncovin (Vincristine), procarbazine, prednisoloneChronic myelogenous leukemia, chronic lymphoblastic leulemia Because of serious toxicity use replaced by less toxic drugs carmustineEstramustine: stable combination of estrogen & mustine designed to deliver mustine to estrogen receptor site of tumor like prostrate cancerAdvantage: both cytostatic and hormonal effect
  • Also used in advanced ovarian tumor, otherwise toxic effects and properties similar to mechlorethamine
  • Pharmacological actions similar to mechlorethamine Prodrug converted in body to active
  • Hemorrhagic cystitis is specific toxicity of cyclophosphamide it is associated with dysuria, hematuria due to irritation of bladder mucosa by acrolein it is dose limiting toxicity. Mesna is also excreted in urine where it binds to and inactivates acrolein Should be given simultaneously and also 4-8 hrs after Acetyl cysteine can also be given Adequate hydration IV mesna (2 mercapto ethane sulfonate )
  • Wegeners granulomatosis
  • Less damaging to the platelets can also cause transverse ridging of nails, increased pigmentation Leucocyte count serves as guide to dosage adjustment in prolonged therapy neutrophil count = 500 to 1000cells /mm3 desired target
  • 1g vial+3 mesna ampoules 200mg for IV Bronchogenic, Breast, Testicular, Bladder , Head & Neck Carcinomas, Osteogenic Sarcoma& some lymphomas
  • Also used in hodkins and other solid tumors
  • Unique in that in conventional doses of busulfan exert few pharmacological actions other than myelosupression Other use- polycythemia vera Pigmentation of skin
  • Streptozocin indicated for T/t of islet cell carcinoma of pancreas 500mg/m2 for 5 days or 1000 mg/m2 weekly
  • Acquired resistance to one alkylating agent often but not always imparts cross resistance to others Guanine –o-alkyl transferase
  • Heavy metal complex has water soluble planar coordination complex containing central platinium atom surrounded by 2 cl and 2 nh3
  • Nephrotoxicity can be reduced by hydration of patients and diuresis by litres of normal saline and mannitol, Hyperuricaemia can occur Neuropathy : large sensory fibres – numbness, tinglingfollowed by loss of joint position and disabling sensory ataxia Ototoxicity : tinnitus and hearing loss in high frequency range , more pronounce in children Rarely shock mutagenic, teratogenic , carcinogenic adverse events reversible on stoppage
  • Excreted by kidneys t1/2 4to 6 hrs Oxaliplatin : less myelosupression but more paresthesia
  • Chemical substance which takes part in cellular metabolic reactions is called metabolite Antimetabolite is a chemical substance which by virtue of its close structural resemblence to metabolite blocks its action it can achieve this by 2 methods By preventing the combination of metabolite with its specific enzyme By itself combining with specific enzyme and getting converted to either metabolically inactive or harmful to cell ( lethal synthesis)
  • One of most commonly used anticancer agents Cell cycle specific drug acts in S phase Methotrexate has antineoplastic, immunosuoressant and anti-inflammatory action It produced the first striking although temporary remission of leukemia and first cure for choriocarcinoma Mechanism of action of methotrexate: methotrexate structurally resembles folic acid , it competitively inhibits dihydrofolate reductase enzyme and blocks conversion of DHFA to THFA THFA is an essential coenzyme required for one carbon transfer reactions in denovo purine synthesis and synthesis of thymidilate , amino acid conversions which are required for DNA SYNTHESIS it also inhibits RNA and protein synthesis. More toxic to rapidly dividing cells likw bone marrow
  • Inhibit erythropoeisis, myelopoesis, and finally aplasia --- marked granulocytopenia , reticulocytopenia
  • Calcium folinate or calcium levofolinate Thymidine also counteracts methotrexate toxicity
  • Choriocarcinoma and tropoblast tumor in women xureRHEUMATOID ARTHRITIS :5-7.5MG PER WEEK ORALLY FOR 8 WEEKSPSORIASIS2.5-5MG AT 12HRLY INTERVALS WEEKLYAlso used in mycosis fungoides , Some role in AML and non hodgkins lymphoma MTP: 25 TO 50 MG ORAL THEN 3-7 DAYS LATER misoprostol 800 microgram vaginally in early part of forst trimester < 8 weeks of gestation
  • 1. Nucleotide formation: To exert its antileukemic effect, 6-MP must penetrate target cells and be converted to the nucleotide analog, 6-thioinosinic acid TIMP. The addition of the ribose phosphate is catalyzed by enzyme, hypoxanthine-guanine phosphoribosyl transferase (HGPRT).2. Inhibition of purine synthesis: A number of metabolic processes involving purine biosynthesis and interconversions are affected by, TIMP. Like adenosine monophosphate (AMP), guanosine monophosphate (GMP), and inosine monophosphate (IMP), TIMP can inhibit the first step of de novo purine-ring biosynthesis (catalyzed by glutamine phosphoribosyl pyrophosphate amidotransferase) by feed back mechanism. TIMP also blocks the formation of AMP and xanthinuric acid from inosinic acid.3. Incorporation into nucleic acids: TIMP is converted to thioguanine monophosphate (TGMP), which after phosphorylation to di- and triphosphates can be incorporated into RNA. The deoxyribonucleotide analogs that are also formed are incorporated into DNA. This results in nonfunctional RNA and DNA.
  • Well absorbed orally, metabolized rapidly by xanthine oxidase, use of xanthine oxidase inhibitor allopurinol decreases the inactivation of 6 MP, xanthine oxidase also required in uric acid synthesis, so allopurinol may be used in cancer chemotherapy to reduce dose of 6 MP and also decrease the hyperuricaemia 6 MP ALSO METABOLISED BY METHYLATION IN PRESENCE OF ENZYME THIOPURINE METHYL TRANSFERASE, GENTIC DEFICIENCY OF THIS ENZYME MAKES INDIVIDUAL MORE SUSCEPTIBLE TO 6 MP toxicity , while over expression is important method of resistance. Azathiprine is also substrate for xanthine oxidase but 6 thiguanine is not.
  • Hyperuricaemia occurs due to massive destruction of cells of lymphoid series , urine should be maintained alkaline and its volume adequate. Other purine analogs like 6 thioguanine and azathiprine also posses cytotoxic actions how ever they do not have any advantage over 6 mercaptopurine as antileukemic agentsMercaptopurine with azathiprine decrease the dose by ¼ to ½ Azathiprine: ImuranUsed as immunosupressive agent in organ transplantation and autoimmune conditons like hemolytic anemia, glomerulonephritis, and rhe umatoid arthritis
  • Promotes tumor apoptosis
  • Extremely effective in complete remission of hairy cell leukemia iv 4 g/m2 alternate week , sufficient hydration 500 ml to 1 l of dextrose in 0.45 % saline
  • 5 fluoro uracil is converted in body to corresponding nucleotide fluorodeoxyuridine monophosphate, Fluorinated analog of pyrimidine acts by inhibiting thymidilate synthesis Also gets incorporated into DNA in place of uracil Uses: topically intreatment of premalignant keratosis Even resting cells are more affected though rapidly multipling cells are more susceptible Toxic to bone marrow , alimentary epitheliumand CNS Administered by slow IV infusion to prevent first pass metabolism.
  • ESPECIALLY IN ADULTS Uses : AML, Hodgkins & Non hodgkinsGemcitabineForms triphosphate that inhibits DNA synthesis Blocks DNA strand elongation Drug of choice in adenocarcinoma of pancreas 1000 mg/m2 over 30 min
  • VX and VBL are both cell-cycle specific and phase specific, because they block mitosis in metaphase (M phase). Their binding to the microtubular protein, tubulin, is GTP dependent and blocks the ability of tubulin to polymerize to form microtubules. Instead, paracrystalline aggregates consisting of tubulindimers and the alkaloid drug are formed. The resulting dysfunctional spindle apparatus, frozen in metaphase, prevents chromosomal segregation and cell proliferationResistance: Resistant cells have been shown to have an enhanced efflux of VX, VBL, and VRB via P-glycoprotein in the cell membrane. Alterations in tubulin structure may also affect binding of the vinca alkaloids.
  • AFE: Unpredictable oral absorption, extensively conc in platelets, vinca alkaloids are not well absorbed by oral routeHighly irritant drugs so given continously by iv infusion, vinca alkaloids are conc and metabolized by CYP450 in liuver excreted in bile in liver dysfunction decrease the dosePhenytoin, phenobarbitone, carbamezepine may induce the metabolism and griseofulvin inhibits metabolism Vinorelbine: semisynthetic derivative for ca breast, testicular cancer, epithelial ovarian cancers.
  • Taxanes bind to beta tubulin subunits of microtubules at a site different from binding site of vinca alkaloids,colchicine, podophyllotoxin, unlike vinca alkaloids they promote polymerization of microtubules & inhibit depolymerization, leading to stabilization of polymerized microtubules and arrests cells in mitosis and eventually leads to activation of apoptosisThe stabilization of microtubules is damaging to cells because of disturbances in in the dynamics of various microtubule dependent structures that are required for functions like mitosis, maintainence of cellular morphology, locomotion and secretion.
  • Dexamethasone, h1 antagonists supress the reaction Abraxane: Albumin bound form of paclitaxel no anaphylactoid reaction
  • Type I topoisomerase cuts one strand of a DNA double helix, relaxation occurs, and then the cut strand is reannealed.Type II topoisomerase cuts both strands of one DNA double helix, passes another unbroken DNA helix through it, and then reanneals the cut strand.Testicular tumors in combination with bleomycin or cisplatinTenoposide used in ALL
  • Topoisomerase I modulates supercoiling of DNA by complexing with it and nicking one of its strands
  • Intercalation in the DNA: The drugs insert nonspecifically between adjacent base pairs and bind to the sugar-phosphate backbone of DNA. This causes local uncoiling and, thus, blocks DNA and RNA synthesis. Intercalation can interfere with the topoisomeraseII–catalyzed breakage/reunion reaction of supercoiled DNA strands, causing irreparable breaks.Generation of oxygen radicals: Cytochrome P450 reductase (present in cell nuclear membranes) catalyzes reduction of the anthracyclines to semiquinone free radicals. These in turn reduce molecular O2, producing superoxide ions and hydrogen peroxide, which mediate single-strand scission of DNA (Figure 39.18). Tissues with ample superoxide dismutase or glutathione peroxidase activity are protected.10 Tumors and heart tissue are generally low in SOD. In addition, cardiac tissue lacks catalase and, thus, cannot effectively scavenge hydrogen peroxide. Lipid peroxidation therefore may explain the cardiotoxicity of anthracyclines.
  • Mechanism of action: The drug intercalates into the minor groove of the double helix between guanine-cytosine base pairs of DNA,8 forming a stable dactinomycin-DNA complex. The complex interferes primarily with DNA-dependent RNA polymerase, although at high doses, dactinomycin also hinders DNA synthesis. The drug also causes single-strand breaks, possibly due to action on topoisomerase II or by generation of free radicals.Adverse effects: The major dose-limiting toxicity is bone marrow depression. The drug is immunosuppressive. Other adverse reactions include nausea, vomiting, diarrhea, stomatitis, and alopecia. Extravasation during injection produces serious problems. Dactinomycin sensitizes to radiation, and inflammation at sites of prior radiation therapy may occur.
  • Acute: ecg changes, arrhythmia, hypotension, delayed CCF Tissues with ample superoxide dismutase or glutathione peroxidase activity are protected.10 Tumors and heart tissue are generally low in SOD. In addition, cardiac tissue lacks catalase and, thus, cannot effectively scavenge hydrogen peroxide. Lipid peroxidation therefore may explain the cardiotoxicity of anthracyclines.
  • Mixture of closely related glycopeptide antibiotics
  • Blocks enzyme Less GI toxicity
  • Methyl hydrazine derivative, inactive as such but undergoes metabolic activation to highly reactive alkylating species which cause methylation of DNA
  • Emit b and gamma radiations disrupt cellular metabolism and cause cellular destruction.
  • Prevent anemia: prevent acceletatederythrocytic destruction, They effectively counter hemolytic and hemorrhagic complications accompanying chronic lymphocytic and malignant lymphomas, Prednisolone is generally started in doses of 60 – 100 mg daily in divided doses and then depending on response reduced to maintenance dose of 20 -40 mg /day The use of this compound in the treatment of lymphomas arose when it was observed that patients with Cushing's syndrome, which is associated with hypersecretion of cortisol, have lymphocytopenia and decreased lymphoid mass. [Note: At high doses, cortisol is also lymphocytolytic and leads to hyperuricemia due to the breakdown of lymphocytes.] Prednisone is primarily employed to induce remission in patients with acute lymphocytic leukemia and in the treatment of both Hodgkin's and non-Hodgkin's lymphomas.Glucocorticoids have some secondary role in hormone responsive breast cancers, they are also valuable for treatment of complications like treatment of hypercalcemia, hemolytic anemias, thrombocytopenia, incresed intracranial tension, mediastinal edema occuring after radiotherapy, they afford symptomatic relief by mood elevating and antipyretic effects and also adjuvants of antiemetics. Useful in treating cerebral edemas due to intracranial cerebral metastasis
  • Fosfesterol is activated to slibesterol in prostatic tissue and acheives high conc in prostatic tissue thus it is used in prostrate cancerAdverse effects – impotence and gynaecomastia
  • SERMS are non steroidal synthetic agents whose agonist or antagonist action on estrogen receptors are tissue selective, produces beneficial estrogenic actions in some tissues (bone, brain, liver), and prevent certain deleterious effect in breast and endometrium by exhibiting antagonistic or no action on ER Tamoxifen: Non steroidal antiestrogen related structuraly to slilbesterol, given orally it competes with the circulating estrogen for cytoplasmic estrogen receptor binding site, the metabolites of tamoxifen have much stronger affinity for receptors and are not easily displaced by circulating estradiol. At low concentration they have cytostatic effect on ER positive cells, higher conc cause cytotoxic effect . Because of antagonistic action in breast DOC in treatment of ca breast in ER+ AS WELL as some ER- breast cancer also male breast
  • Well absorbed orally, biphasic half life 10 hrs and also 7 days, and long duration ofaction some metabolites of tamoxifen are more potent antiestrogens, the drug is excreted primarily in bile. Other SERMS- raloxifene – no risk of endometrial carcinoma, used as first line drug in treatment of postmenopausal osteoporosis, toremifene – new congener of tamoxifen with similar actions uses and adverse effects ORMELOXIFENE – dub, acts as antagonist in breast and uterus
  • USES: Metastatic ER+ Breast Ca in postmenopausal women which has stopped responding to tamoxifenHigher affinity for ER probably accounts for efficacy in tamoxifen resistant cases
  • Aromatization of A ring of testesterone and androstenedione is final and key step in production of estrogensestradiol and estrone in body, in addition to circulating hormone the locally produced hormone may play an important role in breast cancer development, exemestane also aromatase inhibitor
  • cancer chemotherapy

    1. 1. Anti Cancer Chemotherapy
    2. 2. • Cancer – Uncontrolled multiplication and spread within the body of abnormal forms of bodys own cells• Neoplasm – A mass of tissue formed as a result of • Abnormal • Excessive • Uncoordinated • Autonomous and • purposeless Proliferation of cells
    3. 3. Why term chemotherapy• Like infective disease – Some malignant cells can be cultured – Some malignancies can be transmitted by innoculation
    4. 4. Cancer chemotherapy not as successful as antimicrobial chemotherapy• Metabolism in parasite differs qualitatively from host cells, while metabolism in cancer cells differ only quantitatively from normal host cells – Hence target selectivity is more difficult in cancer – cancer there is no substantial immune response – Diagnostic complexity: delay in institution of treatment
    5. 5. Modalities of treatment in cancer• Surgery 1/3 of patients can be cured, effective when tumor has not metastasized• Radiotherapy• Chemotherapy: 50 % of the patients can be treated with chemotherapy contributing to cure in 15 -20 % of patients
    6. 6. Cancer chemotherapy can be curative in• Acute Leukemias• Wilm’s Tumour In children• Ewing’s Sarcoma• Choriocarcinoma• Hodgkin’s Disease• Lymphosarcoma• Burkitts lymphoma• Testicular Teratomas• Seminomas
    7. 7. Chemotherapy can have only Palliative effect in• Breast Cancer• Ovarian Cancer• Endometrial Cancer• Prostatic Cancer• Chronic Lymphatic Leukemia• Chronic Myeloid Leukemia• Head & Neck Cancer• Lung (small cell) Cancer
    8. 8. Chemotherapy is less sensitive in• Colorectal Cancer• Carcinoma Stomach• Carcinoma of esophagus• Renal carcinoma• Hepatoma• Bronchogenic (non small cell) carcinoma• Malignant Melanoma• Sarcoma
    9. 9. Pathogenesis of cancerChemicals, viruses, irradiation, etc Acquired Mutations Inherited Mutations Protooncogenes  oncogenes ↓ expression of tumor supressor genes (P53, Rb etc) Promoters, co-carcinogen, hormones Uncontrolled cell proliferation, ↓ apoptosis, alterations dedifferentiation in telomerase Development of primary tumor
    10. 10. Pathogenesis of cancer Development of primary tumor Production of metalloproteinasesInvasion of nearby tissue by tumor cells Angiogenesis Metastasis Development of secondary tumors
    11. 11. Cancer cells differ from normal cells by • Uncontrolled proliferation • De-differentiation & loss of function • Invasiveness • Metastasis
    12. 12. Guiding principles in cancer chemotherapy• To achieve cure a TOTAL CELL KILL must be tried• Early diagnosis and early institution of treatment• Combination chemotherapy• Intermittent regimens• Adjuvant and neoadjuvant chemotherapy occasionally
    13. 13. Total cell kill• Aimed at destroying all the malignant cells, leaving none• This approach ensures – Early recovery – Prevents relapse – Prolongs survival• Pharmacological sancturies
    14. 14. Effects of various T/t on cancer cell burden
    15. 15. Early diagnosis and early T/t why?• Survival time inversely related to initial number of cells• Aging cancer cells are less susceptible to chemotherapy, because there is – ↑ cell cycle (division) time – ↓No of actively dividing cells with more resting cells – ↑ cell death within tumor – Overcrowding of cells
    16. 16. Combination chemotherapy?• Heterogenicity of cells remaining in different phase of growth cycle , showing different level of sensitivity – Nature of drug (with different biochemical site of action) – Avoid emergence of drug resistance• Monotherapy adequate in Burkitts lymphoma & choriocarcinoma
    17. 17. Why intermittent regimen?• Favours risk –benefit ratio• Allows time for damaged normal host cells to recover• Pulse therapy – Type of intermittent chemotherapeutic regime employing highest tolerated dose within a short administration period – Based on principle of drug conc. (C) x duration of exposure (T) = constant
    18. 18. Adjuvant & Neoadjuvant chemotherapy• Adjuvant chemotherapy: – Chemotherapy given after surgery or irradiation to destroy micrometastasis & prevent development of secondary neoplasm.• Neo-adjuvant chemotherapy: – Chemotherapy given before surgery or radiotherapy in order to diminish the volume of large primary neoplasm
    19. 19. General toxicity of cytotoxic drugs• Nausea & Vomiting• Bone marrow depression• Alopecia• Gonads: Oligospermia, impotence, ↓ ovulation• Foetus: Abortion, foetal death, teratogenicity• Carcinogenicity• Hyperuricemia• Immunosupression: Fludarabine• Hazards to staff
    20. 20. Phases of cell cycle
    21. 21. CLASSIFICATION - I: CELL CYCLE NON SPECIFIC : CELL CYCLE SPECIFIC Kills resting cells & dividing Kills actively dividing cells cells• Cyclophosphamide • G1 – Vinblastine• Chlorambucil • S – Methotrexate• Cisplatin 6-Mercaptopurine• Actinomycin-D 5-Fluorouracil • G2 –Bleomycin• L-asparaginase Etoposide, Topotecan Daunorubicin • M – Vincristine Vinblastine Paclitaxel,Docetaxel
    22. 22. CLASSIFICATION - II: Depending on mechanism at cell level• Directly acting cytotoxic drugs: • Indirectly acting- by – Alkylating agents altering the hormonal – Antimetabolites mileau : – Natural products – Corticosteroids • Antibiotics – Estrogens & ERMs • Vinca alkaloids – 5 alpha reductase inhibitors • Taxanes – Gnrh agonists • Epipodophyllotoxins – Progestins • Camptothecin analogs • Enzymes • Biological response modifiers – Miscellaneous: Cisplatin, carboplatin
    23. 23. Alkylating agents• Nitrogen Mustards – Meclorethamine, Melphalan, Chlorambucil, cyclophosphamide, ifosfamide• Ethyleneimine : Thiotepa• Alkyl Sulfonate: Busulfan• Nitrosureas – Carmustine,lomustine, streptozocin• Triazines – Dacarbazine, temozolamide
    24. 24. Antimetabolites• Folate Antagonists – Methotrexate• Purine Antagonists – 6 Mercaptopurine, 6 Thioguanine, Azathioprine• Pyrimidine antagonists – 5 Fluorouracil, cytarabine, gemcitabine
    25. 25. Natural Products• Antibiotics • Epipodophyllotoxins – Actinomycin D, – etoposide, Doxorubicin, tenoposide Daunorubicin, Bleomycin, • Camptothecin Mitomycin C analogs• Vinca alkaloids – Topotecan, irinotecan – Vincristine, Vinblastine, • Biological response Vinorelbine modifiers• Taxanes – Interferons, – Paclitaxel, docetaxel – Interleukins• Enzymes – L-Asparginase
    26. 26. Miscellaneous Agents• Cisplatin• Carboplatin• Hydroxurea• Procarbazine• Mitotane• Imatinib
    27. 27. Hormones & antagonists• Corticosteroids • Progestins – Prednisolone – Hydroxyprogesterone• Estrogens • Anti-androgens – Ethinyl Estradiol – Flutamide,• SERM Bicalutamide – Tamoxifene, Toremifene • 5- reductase• SERD Inhibitors – finasteride, – Fulvestrant dutasteride• Aromatase Inhibitors • GnRH analogs – Letrozole, Anastrazole, Exemestane – Naferelin, goserelin, leuoprolide
    28. 28. MOA of some anticancer drugsPurine/ Purine & Pyrimidine synthesisPyrimidineantagonists Methotrexate Ribonucleotides Inhibition of purine ring &5 FU inhibits dTMPdTMP synthesis Deoxy ribonucleotides biosynthesisCytarabine inhibitsDNA chain elongation DNA Alkylating agents Alter structure & function of DNADactinomycin , RNA by cross linkingIntercalate with DNA and/ordisrupt DNA function fragmenting DNA Proteins
    29. 29. Alkylating agents• Nitrogen Mustards (MCI) – Meclorethamine, Melphalan, Chlorambucil, Cyclophosphamide, Ifosfamide• Ethyleneimine : Thiotepa• Alkyl Sulfonate: Busulfan• Nitrosureas – Carmustine,lomustine, streptozocin• Triazines – Dacarbazine, temozolamide
    30. 30. Mechanism of action Alkylating Agents Form highly reactive carbonium ion Transfer alkyl groups to nucleophilic sites on DNA bases Results inCross linkage Abnormal base pairing DNA strand breakage Alkylation also damages RNA ↓ cell proliferation and proteins
    31. 31. Pharmacological actions• Cytotoxic action – Hemopoetic system highly susceptible • Chlorambucil – more against lymphoid series • Busulfan – more against myeloid series – Epithelial tissues, hair follicles – Spermatogenesis , fetopathic effect• Immunosupressant action• Miscellaneous – Severe nausea & vomiting• Known as radiomimetic drugs
    32. 32. Nitrogen Mustards• Mechlorethamine• Melphalan• Chlorambucil• Cyclophosphamide• Ifosfamide
    33. 33. Mechlorethamine (Mustine)• Very irritant drug• Dose = 0.4 mg/kg single or divided• Uses – Hematological cancers , lymphomas , solid tumors – Hodkins as part of MOPP, CML, CLL• Adverse effects – Anorexia, nausea, vomiting – Bone marrow depression, aplasia – Menstrual irregularities• Estramustine
    34. 34. Melphalan• Very effective in MULTIPLE MYELOMA• Less irritant locally , less alopecia• Dose: 0.25 mg/kg daily for 4 days every 4-6 weeks• Adverse Effects : – Bone marrow Depression – Infections , diarrhoea and pancreatitis
    35. 35. Cyclophosphamide• Most commonly used alkylating agent a prodrug
    36. 36. Cyclophosphamide Cyclophosphamide AldophosphamidePhosphoramide Acroleinmustard Hemorrhagic cystitisCytotoxic effect Mesna
    37. 37. Uses of cyclophosphamide• Neoplastic conditions – Hodgkins and non hodgkins lymphoma – ALL, CLL, Multiple myeloma – Burkits lymphoma – Neuroblastoma , retinoblastoma – Ca breast , adenocarcinoma of ovaries• Non neoplastic conditions – Control of graft versus host reaction – Rheumatoid arthritis – Nephrotic syndrome
    38. 38. Cyclophosphamide• Adverse effects: – Hemorrhagic cystitis, – alopecia, – nausea & vomiting, – SIADH – hepatic damage• Dose: 2-3 mg/kg/day oral 10-15 mg/kg IV every 7-10 days• It can be administered IV, IM, IP, intrapleurally, Intraarterialy, directly into tumor
    39. 39. Ifosfamide• Congener of cyclophosphamide• Longer half life than cyclophosphamide• Less alopecia and less emetogenic than cyclophosphamide• Can cause hemorrhagic cystitis and severe neurological toxicity• Used for germ cell testicular tumors and adult sarcomas
    40. 40. Chlorambucil (Leukeran)• Slowest acting and least toxic alkylating agent• Main action on lymphoid series produces marked lympholytic action• Drug of choice for long term maintenance therapy of CLL• Dose: 0.1-0.2 mg/kg daily for 3-6 weeks then 2 mg daily for maintenance
    41. 41. ThioTEPA• Triethylene phosphoramide• Does not require to form active intermediate• Active intravesicular agent can also be used topicaly in superficial bladder cancer• Not well absorbed orally given IV• High toxicity
    42. 42. Busulfan (Myleran)• Depresses bone marrow with selective action on myeloid series• Primarily used in Chronic myelogenous leukemia 2-6 mg/day• Adverse effect: – Interstitial pulmonary fibrosis – Venoocclusive disease of liver – Hyperuricaemia – Sterility
    43. 43. Nitrosureas• Highly lipid soluble, Cross BBB• Uses: – Meningeal / Brain tumours• Dose :150-200 mg/m2 BSA every 6 wks (Carmustine)• Adverse Effects: – Delayed bone marrow suppression – Visceral fibrosis, renal damage
    44. 44. Triazenes• Dacarbazine – Primary inhibitory action on RNA & protein synthesis – Used in malignant melanoma• Temozolamide – New alkylating agent – Approved for malignant glioma – Rapidly absorbed after oral absorption & crosses BBB
    45. 45. Mechanisms of resistance of alkylating agents • ↓ Influx of drug • ↑ Production of nucleophilic substances like glutathione that compete with target DNA for alkylation • ↑ Activity of DNA repair enzymes • ↑ metabolic inactivation of drugs
    46. 46. Cisplatin• Non cell cycle specific Cl NH3 killing Pt• Administered IV Cl NH3• Highly bound to plasma proteins Dose: 20 mg/m2 for 5 days a• Gets conc in kidney, week intestine, testes 75 – 100 mg/m2 once in• Poorly penetrates BBB 4 weeks to treat ovarian cancer• Slowly excreted in urine
    47. 47. Mechanism of action of cisplatin Cisplatin enters cells Cl- Forms highly reactive platinum complexes Intra strand & interstrand cross links DNA damage Inhibits cell proliferation
    48. 48. Cisplatin uses and adverse effects• Uses – Testicular cancer (85% - 95 % curative ) – Ovarian cancer – Other solid tumors: lung, esophagus, gastric• Adverse effects – Emesis – Nephrotoxicity – Peripheral neuropathy – Ototoxicity
    49. 49. Carboplatin• Better tolerated• Nephrotoxicity , ototoxicity , neurotoxicity low• Less emetogenic• But thrombocytopenia and leukopenia may occur• Less plasma protein binding• Use: – primarily in ovarian cancer of epithelial origin – Squamous cell carcinoma of head and neck
    50. 50. Antimetabolites• Folate Antagonists – Methotrexate• Purine Antagonists – 6 Mercaptopurine, 6 Thioguanine, Azathioprine• Pyrimidine antagonists – 5 Fluorouracil, cytarabine, gemcitabine
    51. 51. Methotrexate Folic acid not useful in toxicity Folinic acid N5 formyl FH4 should be given which is converted to N5,N10- Methylene –FH4 and bypasses the inhibited reductase Adenine, guanine, thymidine , methionine, serine
    52. 52. Pharmacological actions• Cytotoxic actions – Predominant on bone marrow – Ulceration of intestinal mucosa – Crosses placenta interferes with embroyogenesis foetal malformations and death• Immunosupressive action – Prevents clonal expansion of B & T lymphocytes• Anti-Inflammatory action – Interferes with release of inflammatory cytokines IL-2, IL-6,IL-8 & TNF- , ↓ Rheumatoid Factor production
    53. 53. Pharmacokinetics• Absorbed orally, 50 % protein bound• Disappears rapidly from blood , remains in tissue longer than folate thus causes prolonged inhibitory effect• C/I in renal impairment
    54. 54. Adverse effects• Megaloblastic anemia• Thrombocytopenia, leukopenia, aplasia• Oral, intestinal ulcer , diarrhoea• Alopecia , liver damage, nephrpathy Treatment of methotrexate toxicity  Folinic acid (citrovorum factor, N5 Formyl THF)  IM/IV 8 to 24 hrs after initiation of methotrexate  120 mg in divided doses in first 24 hrs, then 25 mg oral/IM 6 hrly for next 48 hrs
    55. 55. Uses of methotrexate• Antineoplastic – Choriocarcinoma and tropoblast tumor 15 -30 mg/day orally for 5 days – Remission of ALL in children 2.5 to 15 mg/day – Ca breast, head & neck, bladder, ovarian cancer• Immuno-supressive agent – Rheumatoid arthritis, resistant asthma – Crohns disease, wegeners granulomatosis – Prevention of graft versus host reaction• Psoriasis• Medical termination of pregnancy
    56. 56. Purine antagonists• 6 Mercaptopurine• 6 Thioguanine• Azathioprine• Fludarabine
    57. 57. 6 Mercaptopurine HGPRT Ribonucleotide(HGPRT):hypoxanthine-guaninephosphoribosyl transferase
    58. 58. 6 Mercaptopurine Allopurinol 6 MPTPMT Xanthine oxidase 6 Thiouric acidInactivemetabolite
    59. 59. 6 Mercaptopurine• Use: – Acute leukemia (ALL) – Choriocarcinoma• Adverse Effects: – Bone marrow & GIT mainly – Hepatic necrosis rarely – Hyperuricaemia
    60. 60. Fludarabine• Phosphorylates intracellularly to form triphosphate• Inhibits DNA polymerase and gets incorporated to form dysfunctional DNA• Effective in slow growing tumors: (apoptosis)• Use: – CLL and non hodgkins recurring after treatment• Adverse events: – chills, fever, opportunistic infection, myelosupression
    61. 61. Cladirabine• Like fludarabine converted to triphosphate• Incorporated into DNA• Inhibits DNA polymerase and thus inhibits DNA synthesis and repair• Used in treatment of Hairy cell leukemia, CLL and low grade lymphomas
    62. 62. Pentostatin Inhibits adenosine deaminaseAccumulation of adenosine & deoxyadenosine Inhibits ribonucleotide reductase Blocks DNA synthesis S adenosyl homocysteine accumulation Toxic to lymphocytes Used in Hairy cell leukemia
    63. 63. Pyrimidine antagonists• 5 fluoruracil• Cytosine arabinoside (Cytarabine)• Gemcitabine
    64. 64. 5 fluorouracil 5 FU FdUMP FdUMP = fluorodeoxyuridine monophosphate Thymidilate synthetase Thymidine dUMP MonophosphateUses : stomach , colon, DNA Synthesisbreast ovaries , liver, skin (Selective failure)cancers
    65. 65. Cytosine arabinoside• Pyrimidine analog considered drug of choice in inducing remission in AML• Phosphorylated in body to triphosphate• Triphosphate of cytarabine inhibits DNA polymerase &• Thus inhibit DNA synthesis and repair Gemcitabine• Drug of choice in adenocarcinoma of pancreas
    66. 66. Vinca alkaloids• Obtained from periwinkle plant ( Vinca Rosea)• Vincristine, vinblastine, vindesine, vinorelbine
    67. 67. Mechanism of action
    68. 68. Comparison between Vincristine Vinblastine• Marrow sparing effect • Bone marrow supression• Alopecia more common • Less common• Peripheral & autonomic • Less common, temp. neuropathy & muscle mental depresssion weakness (CNS) • Nausea, vomiting,• Constipation diarrhoea• Uses: (Childhood cancers) • uses – ALL , Hodgkins, lymphosarcoma, – Hodgkins disease & other Wilms tumor, Ewings sarcoma lymphomas , breast cancer, testicular cancer
    69. 69. Taxanes• Paclitaxel & docetaxel• Plant product obtained from bark of Pacific Yew ( Taxus Brevifolia) & European Yew (Taxus Buccata)
    70. 70. Mechanism of actionCell cycle arrested in G2 and M phase
    71. 71. • Paclitaxel – Administered IV – Use: advanced breast & ovarian cancer also lungs, esophagus, prostrate cancer – Adverse effects: • Anaphylactoid reaction because of solvent cremaphor • Myalgia, myelosupression, peripheral neuropathy• Docetaxel – Oral – Used in refractory breast & ovarian cancer – Major toxicity neutropenia may cause aarrhythmias , hypotension
    72. 72. Epipodophyllotoxins• Etoposide & tenoposide• Semisynthetic derivatives of podophyllotoxins podophyllum peltatum (plant glycoside)
    73. 73. Etoposide• Act in S & G2 phase• Inhibit topoisomerase II which results in breakage of DNA strands & cell death• Uses: – Testicular tumors , squamous cell cancer of lungs
    74. 74. Camptothecin analogs• Derived from camptotheca accuminata• Inhibit Topoisomerase I: No resealing of DNA after strand has untwisted• Topotecan: – Used in metastatic ovarian cancer – Major toxicity is bone marrow depression• Irinotecan – Used in metastatic cancer of colon/rectum – Toxicity: diarrhoea, neutropenia, thrombocytopenia, cholinergic side effects
    75. 75. Anticancer antibiotics• Cell cycle non specific drugs• Derived from streptomyces species• MOA: – Intercalation in the DNA between adjoining nucleotide pairs – blocks DNA & RNA synthesis – Generation of oxygen radicals which mediate single strand scission of DNA – Action on Topoisomerase II
    76. 76. Dactinomycin• Uses: – Wilms tumor, – gestational choriocarcinoma• Adverse effects – bone marrow supression – Irritant like meclorethamine – sensitizes to radiation, and inflammation at sites of prior radiation therapy may occur – Gastrointestinal adverse effects
    77. 77. Doxorubicin & Daunorubucin
    78. 78. • Doxorubicin: – Used in acute leukemias, malignant lymphoma and many solid tumors, direct instillation in bladder cancer• Daunorubicin: – Use limited to ALL and granulocytic leukemias• Toxicity: – Both cause cardiotoxicity (cardiomyopathy) – Marrow Depression, Alopecia
    79. 79. • Mitoxantrone – Analog of doxorubicin – Lower cardiotoxicity – Uses: Acute leukemia, CML, Non hodgkins• Mitomycin C – Highly toxic used only in resistant cancers of stomach, colon, rectum – Transformed to form which acts like alkylating agent• Mithramycin – Reduces blood calcium levels by inhibiting osteoclasts – Used in T/t of hypercalcemia with bone metastasis
    80. 80. BleomycinReacts with iron, DNA – bleomycin – Fe2+copper & O2 inpresence of CYP -450 DNA – bleomycin – Fe3+reductaseAlso can intercalatebetween DNA strands
    81. 81. Bleomycin• Uses : – Epidermoid cancers of skin, oral cavity, genitourinary tract, esophagus – Testicular tumors – Hodgkins lymphoma• Adverse effects: – Pneumonitis – Fatal pulmonary fibrosis – Hyper pigmentation – spares bone marrow
    82. 82. L-asparaginase
    83. 83. L-asparaginase• Isolated from E.coli• Use: Acute Lymphocytic Leukemia (ALL)• Dose : • 6000 to 10000U/kg IV daily for 3-4 weeks• A/E: • Hepatic damage • Hypersensitivity , hemorrhage • Hyperglycemia, headache, hallucinations , confusion, coma
    84. 84. Hydroxyurea Ribonucleoside diphosphate reductaseRibonucleotides Deoxyribonucleotides Hydroxyurea• Uses: • Adverse effects • CML, Polycythemia, • Myelosuppression psoriasis (Minimal)• Dose: • Hypersensitivity • 20-30 mg/kg /day • Hyperglycemia orally • Hypoalbuminemia
    85. 85. Procarbazine• MOA: Depolymerizes DNA & causes chromosomal damage• USES: Hodgkin’s disease ( MOPP regimen) • Non hodgkins lymphoma• 100-200mg daily orally• A/e: MAO inhibitor action & antabuse action
    86. 86. Radio active isotopes• I131 – Emits beta radiation , half life-8.04 days use:Follicular Ca- Thyroid• P32 - Emits beta radiation , half life- 14.3 days. use : Polycythemia vera• 198Au – gives low energy beta & gamma radiation, half life- 2.69 days use :malignant pleural, peritoneal effusion
    87. 87. Hormones & antagonists• Corticosteroids • Progestins – Prednisolone – Hydroxyprogesterone• Estrogens • Anti-androgens – Ethinyl Estradiol – Flutamide,• SERM Bicalutamide – Tamoxifene, Toremifene • 5- reductase• SERD Inhibitors – finasteride, – Fulvestrant dutasteride• Aromatase Inhibitors • GnRH analogs – Letrozole, Anastrazole, Exemestane – Naferelin, goserelin, leuoprolide
    88. 88. Glucocorticoids• Marked lympholytic effect so used in acute leukaemias & lymphomas,• They also – Have Anti-inflammatory effect – Increase appetite, prevent anemia – Produce sense of well being – Increase body weight – Supress hypersensitivity reaction – Control hypercalcemia & bleeding – Non specific antipyretic effect – Increase antiemetic effect of ondansetron
    89. 89. Estrogens• Physiological antagonists of androgens• Thus used to antagonize the effects of androgens in androgen dependent prostatic cancer• Fofesterol – Prodrug , phosphate derivative of stilbesterol – 600-1200mg IV initially later 120-240 mg orally
    90. 90. Selective Estrogen Receptor Modulators (SERMs) • Tamoxifen : Non steroidal antiestrogenAntagonistic: Agonistic:Breast and Uterus,blood vessels bone, liver, pitutary
    91. 91. Tamoxifen• DOSE:10-20mg bd• Standard hormonal treatment in breast cancer• Adverse effects: – Hot flushes , vomiting, vaginal bleeding, menstrual irregularities, venous thromboembolism, dermatitis, rarely endometrial cancer
    92. 92. Selective Estrogen Receptor Down regulator (fulvestrant)• Pure estrogen antagonist• USES: Metastatic ER+ Breast Ca in postmenopausal women• MOA: • Inhibits ER dimerization & prevents interaction of ER with DNA • ER is down regulated resulting in more complete supression of ER responsive gene function
    93. 93. Aromatase Inhibitors• Letrozole • Orally active non steroidal compound • MOA : Inhibits aromatisation of testosterone & androstenedione to form estrogen. • Uses : Breast Ca- & adj. to mastectomy • Dose :2.5mg bd orally• Anastrozole : more potent • 1mg OD in ER+ Breast Ca • A/E : hot flushes
    94. 94. Anti androgens• FLUTAMIDE & BICALUTAMIDE : • Androgen Receptor antagonists • Dose : 250 mg tds, 50mg od resp. • Palliative effect in metastatic Prostatic Ca after orchidectomy
    95. 95. 5- reductase inhibitors Finasteride• Orally active Prostate volume• DHT levels ↓ Symptom score• Benign prostatic Peak urine flow hyperplasia rateDose: 5mg/day DHT level in prostate Also used for prevention of hair lossSide effects: Loss of libido & impotence in 5 % pts.
    96. 96. GnRH agonists• NAFERELIN : nasal spray / SC inj• ↓FSH & LH release from pituitary- ↓ the release of estrogen & testosterone• USE : Breast Ca, Prostatic Ca• PROGESTINS:• Hydroxyprogesterone – used in metastatic endometrial Ca.• A/E: bleeding
    97. 97. Newer anticancer drugs• Inhibitors of growth factors receptors – Imatinib: CML (BCR-ABL gene) – Gefitinib: Non small cell cancer of lungs (EGFR) – Nilotinib : CML (Tyrosine kinase inhibitor) – Dasatinib : CML (Tyrosine kinase inhibitor) – Lapatinib : metastatic breast cancer (HER2/neu) – Sunitinib : renal cell carcinoma (VEGF) – Sorafinib : renal cell carcinoma (VEGF)
    98. 98. Newer anticancer drugs• Monoclonal antibodies – Trastuzumab : breast cancer (HER2/neu) – Bevacizumab: metastatic colon cancer (VEGF) – Rituximab : non hodgkins lymphoma (CD-20) – Panitumumab : metastatic colon cancer (EGFR) – Alemtuzumab : CLL (CD 52 antigen) – Iodine tositumonab : Non hodgkins (CD-20)
    99. 99. Important drug combinationsREGIMEN CANCER DRUGSMOPP Hodgkins Mechlorethamine, oncovin, prednisolone, procarbazineABVD Hodgkins Doxorubicin, bleomycin, vinblastine, dacarbazineCMF Breast Cyclophosphamide, methotrexate, 5-FUCAF Breast Cyclophosphamide, doxorubicin, 5FU ALL Vincristine, prednisolone, aspargine, daunorubicin AML Cytarabine, methotrexate CML Hydroxyurea, interferon Wilms Actinomycin, vincristine, doxorubicin
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.